ASX:TLC 19 February 2026

April 2, 2026, 4:43 AM EDT. Arvinas Inc (ARVN) shares jumped 6.9% to close at $11.33, supported by higher than normal trading volume. The increase follows promising clinical data from its experimental drug ARV-102 targeting LRRK2, a protein linked to Parkinson's disease. Early-stage results showed a 50% or greater reduction of LRRK2 protein in cerebrospinal fluid by day 14, sustained through day 28. Despite this optimism, Arvinas is expected to report a quarterly loss of $0.94 per share, a 182.5% year-over-year decline, with revenues forecasted down 91%. Earnings estimate revisions for the quarter have trended slightly downward, commonly a bearish signal for stock price. The stock holds a Zacks Rank #3 (Hold), reflecting cautious investor sentiment amid mixed fundamentals and promising pipeline developments.